ZNF691 Inhibitors
ZNF691 inhibitors encompass a diverse range of chemical compounds that act upon various cellular signaling pathways, ultimately leading to the diminished functional activity of ZNF691. Staurosporine and chelerythrine, through their actions as kinase inhibitors, potentially reduce the phosphorylation state of proteins that could be crucial for ZNF691 activity, hence impeding its proper function. U0126 and PD 98059, both targeting the MEK enzyme in the MAPK/ERK pathway, would decrease the ERK-mediated signaling events that may augment ZNF691 activity. Furthermore, LY 294002 and Wortmannin specifically target the PI3K/Akt pathway, which, if involved in the activation of ZNF691, would see its activity curbed as a result of these inhibitors. Rapamycin's role as an mTOR inhibitor implies a reduction inmTORC1 signaling, which may be indispensable for ZNF691 activity, thus rapamycin's use would consequentially lead to a decrease in ZNF691's functional activity.
Similarly, SB 203580, by inhibiting p38 MAPK, could interfere with any potential enhancement of ZNF691 function mediated by this pathway. Bortezomib induces ER stress and could negatively impact ZNF691 if its function is affected by protein misfolding responses. Nutlin-3, by stabilizing p53, might indirectly lead to the downregulation of ZNF691 if the latter is subject to p53-mediated control. GW 5074, by inhibiting Raf-1, affects the MAPK/ERK signaling and would thereby indirectly impede any Raf-1 dependent regulation of ZNF691. SP600125 targets JNK signaling, which, if involved in the functional regulation of ZNF691, would result in a functional decrease upon inhibition. Together, these inhibitors, through their concerted action on discrete signaling pathways, orchestrate a comprehensive downregulation of ZNF691, each compound contributing to the cumulative effect of decreased ZNF691 activity without affecting its expression levels directly.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that can diminish the activity of a broad range of kinases. If ZNF691 function is regulated by phosphorylation through certain kinases, staurosporine could indirectly lead to its functional inhibition by preventing necessary phosphorylation events. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK inhibitor that suppresses the MAPK/ERK pathway. Assuming ZNF691 activity is modulated through this pathway, U0126 would lead to a decrease in ERK-mediated signaling events that might otherwise enhance ZNF691 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that could diminish the PI3K/Akt signaling pathway. If ZNF691 is activated by the PI3K/Akt pathway, inhibiting this pathway with LY 294002 would result in reduced functional activity of ZNF691. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can reduce mTORC1 signaling. If the functional activity of ZNF691 is enhanced by mTORC1 signaling, rapamycin would then diminish ZNF691's functional activity by inhibiting this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that can impede the p38 MAPK signaling pathway. If ZNF691 is activated downstream of or is stabilized by p38 MAPK, inhibition by SB 203580 would lead to decreased ZNF691 function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that can lead to the accumulation of misfolded proteins, triggering ER stress. If the functional activity of ZNF691 is sensitive to ER stress, bortezomib could indirectly inhibit ZNF691 function by enhancing misfolded protein response and potentially altering its stability or processing. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor, which could also diminish ZNF691 activity if it is regulated by the PI3K/Akt pathway by preventing the activation of this pathway. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
As an MDM2 antagonist, Nutlin-3 stabilizes p53, leading to cell cycle arrest and apoptosis. If ZNF691 is degraded by MDM2 or its activity is repressed in a p53-dependent manner, Nutlin-3 could indirectly lead to the functional inhibition of ZNF691 by stabilizing p53. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
A Raf-1 inhibitor that could diminish MAPK/ERK signaling. If ZNF691's activity requires Raf-1 mediated signaling, GW 5074 would indirectly inhibit ZNF691 activity by inhibiting this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. If ZNF691 is regulated by ERK signaling, PD 98059's inhibition of MEK would lead to a downstream decrease in ZNF691 functional activity. | ||||||